Ken Haas


  • LocationSan Francisco
  • ExpertiseVenture Capital, Clinical Co-development

Ken retired in 2020 but continues to support Abingworth in an advisory capacity. He spent 25 years in the management of both early-stage and public high technology and biotechnology companies. His directorships included eFFECTOR, Gynesonics, Intellikine, SFJ Pharmaceuticals and Zogenix.

He was part of the founding management team at IntelliGenetics, one of the world’s first bioinformatics companies and CEO of IntelliCorp, a publicly-traded enterprise software company. At the beginning of his career he practised as an attorney in the business and technology group of Heller, Ehrman, White & McAuliffe, and has been Co-Chair of the Advisory Council to the Neuroscience Institute at Stanford. He received his BA from Harvard College, an MA from the University of Sussex and a JD from Harvard Law School.